CNSP Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-5.090

-98.86%

-7.610

-59.86%

-1.240

-80.69%

Estimates Revision

The market is revising No Change the revenue expectations for CNS Pharmaceuticals, Inc. (CNSP) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -42.09%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-42.09%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast CNSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNSP is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

20.00

Averages

20.00

High

20.00

Current: 0.000

Low

20.00

Averages

20.00

High

20.00

UBS

Neutral

maintain

$63 -> $66

2026-01-08

New

Reason

UBS

Price Target

$63 -> $66

2026-01-08

New

maintain

Neutral

Reason

UBS raised the firm's price target on Centerspace to $66 from $63 and keeps a Neutral rating on the shares. 2026 is expected to mark a pivotal REIT turnaround, with forecast total returns of 9%-11% driven by improving macro conditions, attractive valuations, easing supply pressures, and a more stable political backdrop, the analyst tells investors in a research note. The outlook points to a bifurcated year with defensiveness in the first half of 2026 and stronger catalysts in the second half, favoring Healthcare, Shopping Centers, and Coastal Apartments, UBS says.

Cantor Fitzgerald

Richard Anderson

Neutral

maintain

$62 -> $65

2026-01-05

New

Reason

Cantor Fitzgerald

Richard Anderson

Price Target

$62 -> $65

2026-01-05

New

maintain

Neutral

Reason

Cantor Fitzgerald analyst Richard Anderson raised the firm's price target on Centerspace to $65 from $62 and keeps a Neutral rating on the shares. U.S. equity REITs returned 2.9% in 2025, lagging the S&P 500, but 2026 may offer optimism with a potentially more supportive macro environment and an accelerating M&A theme, the analyst tells investors in a research note. Stable supply and demand fundamentals, balance sheet strength, and a well-covered, growing 4% dividend yield make the sector attractive despite past underperformance, Cantor adds.

Maxim

Hold

Buy

upgrade

$20

2025-09-12

Reason

Maxim

Price Target

$20

2025-09-12

upgrade

Hold

Buy

Reason

Maxim upgraded CNS Pharmaceuticals to Buy from Hold with a $20 price target.

Maxim

Hold

Buy

upgrade

$20

2025-09-12

Reason

Maxim

Price Target

$20

2025-09-12

upgrade

Hold

Buy

Reason

As previously reported, Maxim upgraded CNS Pharmaceuticals to Buy from Hold with a $20 price target. The company has pivoted to its oncology asset TPI-287, a blood brain barrier crossing taxane in development initially for recurrent glioblastoma, the analyst tells investors in a research note. Maxim further cites CNS Pharma's road map for TPI-287, as well as a potential path forward with Berubicin and cash runway into the second half of 2026, as positioning the stock toward a recovery.

Alliance Global Partners

James Molloy

Buy

maintain

$4 -> $7

2025-05-22

Reason

Alliance Global Partners

James Molloy

Price Target

$4 -> $7

2025-05-22

maintain

Buy

Reason

Alliance Global Partners analyst James Molloy raised the firm's price target on CNS Pharmaceuticals to $7 from $4 pre-reverse-split and keeps a Buy rating on the shares after the company announced Q1 results and a quarterly update last week. The company recently pivoted to focusing on its TPI-287 candidate for Glioblastoma Multiforme after its lead candidate berubicin failed to meet the primary endpoint of a pivotal Phase 2 trial, notes the analyst, who is removing berubicin from the firm's valuation. The firm, which notes that CNS executed a 50:1 reverse split in Q1, values TPI-287 at $5.25 per share and cash and technology at $1.75 per share.

Maxim Group

Jason McCarthy

Strong Buy

Hold

Downgrades

n/a

2025-03-25

Reason

Maxim Group

Jason McCarthy

Price Target

n/a

2025-03-25

Downgrades

Strong Buy

Hold

Reason

Maxim analyst Jason McCarthy downgraded CNS Pharmaceuticals to Hold from Buy after the company reported that the primary analysis of its clinical trial evaluating Berubicin for the treatment of recurrent or progressive Glioblastoma Multiforme did not demonstrate statistically significant superiority in overall survival, the primary endpoint.

Valuation Metrics

The current forward P/E ratio for CNS Pharmaceuticals Inc (CNSP.O) is -0.46, compared to its 5-year average forward P/E of -2.83. For a more detailed relative valuation and DCF analysis to assess CNS Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.83

Current PE

-0.46

Overvalued PE

4.59

Undervalued PE

-10.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CNSP News & Events

Events Timeline

No data

News

7.5

2025-09-16Benzinga

Webtoon Entertainment Shares Surge 48%; Check Out 20 Stocks Making Moves in Premarket Trading

4.0

2025-09-13Yahoo Finance

CNS Pharmaceuticals Receives Buy Rating from Maxim Following TPI-287 Development Plan

9.0

2025-08-27Newsfilter

IBN Unveils New Episode of The BioMedWire Podcast with CNS Pharmaceuticals Inc. CEO John Climaco

People Also Watch

Frequently Asked Questions

What is CNS Pharmaceuticals Inc (CNSP) stock price today?

The current price of CNSP is 5.82 USD — it has decreased -2.02 % in the last trading day.

What is CNS Pharmaceuticals Inc (CNSP)'s business?

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.

What is the price predicton of CNSP Stock?

What is CNS Pharmaceuticals Inc (CNSP)'s revenue for the last quarter?

CNS Pharmaceuticals Inc revenue for the last quarter amounts to -3.25M USD, decreased -42.20 % YoY.

What is CNS Pharmaceuticals Inc (CNSP)'s earnings per share (EPS) for the last quarter?

CNS Pharmaceuticals Inc. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for CNS Pharmaceuticals Inc (CNSP)'s fundamentals?

How many employees does CNS Pharmaceuticals Inc (CNSP). have?

CNS Pharmaceuticals Inc (CNSP) has 4 emplpoyees as of January 10 2026.

What is CNS Pharmaceuticals Inc (CNSP) market cap?

Today CNSP has the market capitalization of 3.61M USD.